Market revenue in 2023 | USD 88.4 million |
Market revenue in 2030 | USD 151.3 million |
Growth rate | 8% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.57% in 2024. Horizon Databook has segmented the Middle East & Africa in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
An increasing number of R&D projects and life sciences companies in the region is expected to boost market growth during the forecast period. The country is adopting global standards and collaborating with other global CROs to mark its market presence.
Moreover, MEA in vivo CRO industry offers advantages like world-class medical facilities, well-developed infrastructure, and low operational cost, thereby boosting market growth.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account